FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Real-time Bid/Ask 08:07:08 28/05/2024 BST | ||
| 8.95 EUR / 9.12 EUR | -17.41% |
|
| Current month | +12.90% | ||
| 1 month | +7.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 9.04 | -17.37% |
| 27/05/24 | 10.94 | +17.01% |
| 24/05/24 | 9.35 | -8.33% |
| 23/05/24 | 10.2 | +3.45% |
| 22/05/24 | 9.86 | -6.18% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 07:34 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1XQ3 |
| ISIN | DE000MG1XQ33 |
| Date issued | 09/04/2024 |
| Strike | 771.2 kr |
| Maturity | Unlimited |
| Parity | 2.33 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.17 € |
|---|---|
| Lowest since issue | 7.77 € |
| Spread | 0.42 € |
| Spread % | 4.46% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
617
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.32%
- Stock Market
- Certificates
- Certificat
